Montreal, June 23, 2021 – Ferring Canada, in discussions with the Canadian Hemophilia Society, has stated that supply of DDAVP, the 15 mcg/mL formulation of desmopressin, injected subcutaneously, for the treatment of mild hemophilia A, Type 1 von Willebrand disease and platelet disorders, will resume in “one or two months.” The shortage was apparently caused by shipping issues. Ferring had earlier cited a global manufacturing issue to explain the stoppage in supply to Canadian pharmacies.
The worldwide production of Octostim Spray, inhaled through the nose, remains stopped and is not expected to resume until 2023.
Patients who use either of the formulations should contact their treatment centre for advice on alternatives.
Montreal, June 17, 2021 – The CHS has just learned that Ferring, the manufacturer of the 15 mcg/mL injectable formulation of DDAVP for the treatment of mild hemophilia A and Type 1 von Willebrand disease and platelet disorders, has halted global production. No reason has been given for the manufacturing stoppage and there is no timetable for a resumption in supply. As a result, hospital and community pharmacies are unable to replenish supply and inventory is low.
This follows an indefinite stop in the worldwide production of Octostim Spray, inhaled through the nose, in 2020.
The less concentrated 4 mcg/mL formulation remains on the market. It is, however, far from ideal, as it must be infused intravenously, or if injected subcutaneously, must be given in larger volumes.
Patients who use either of the discontinued formulations should contact their treatment centre for advice on alternatives.
Meanwhile, the CHS, in collaboration with the World Federation of Hemophilia, will advocate for the earliest possible resumption in supply.
